GlassScriptPhysician profile
Rafael E Calderon-Rodriguez
NPI 1669421830
$6,924.44
in general payments reported to CMS, 2019-2025
21 companies · $1,800 in 2025
The $1,800 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,507 · 2020: $171 · 2021: $498 · 2022: $1,111 · 2023: $433 · 2024: $405 · 2025: $1,800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,500 · Food and Beverage: $1,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,500.00 |
| Food and Beverage | $1,137.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,846.74 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $1,770.58 | 2019-2025 | Pneumovax 23, Capvaxive |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $817.08 | 2019-2025 | Lifevest |
| Amgen INC. | $619.41 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $457.86 | 2019-2025 | Camzyos |
| United Therapeutics Corporation | $297.19 | 2021-2022 | |
| Abbott Laboratories | $136.08 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.50 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $123.28 | 2019-2022 | |
| Impulse Dynamics (USA) INC. | $121.91 | 2023 | Optimizer |
| Medtronic, INC. | $119.48 | 2024 | Vantage Anterior Fixation System, Linq II, Micra |
| Janssen Pharmaceuticals, INC | $117.53 | 2019-2022 | |
| Verity Pharmaceuticals INC. | $115.39 | 2023 | Vibativ |
| Novartis Pharmaceuticals Corporation | $73.40 | 2019-2022 | |
| Boston Scientific Corporation | $68.86 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pbg Puerto Rico LLC | $29.51 | 2019-2021 | |
| Biotronik INC. | $24.49 | 2019 | |
| Sanofi-Aventis U.S. LLC | $23.92 | 2019 | |
| Gilead Sciences, INC. | $17.58 | 2019 | |
| Akcea Therapeutics, INC. | $15.65 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafael Calderon-Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.